Feb 5 (Reuters) - Shanghai Henlius Biotech Inc 2696.HK:
SERPLULIMAB APPROVED IN THE EU FOR FIRST-LINE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Source text: ID:nPn1dClhYa
Further company coverage: 2696.HK
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.